Molbio Diagnostics IPO Set for Listing as GMP Surges; Allotment Status Expected Today
The highly anticipated Molbio Diagnostics Initial Public Offering (IPO) is poised to conclude its allotment process today, bringing the journey of this molecular diagnostics company closer to a market debut. Investors who participated in the ₹939.70-crore issue can now monitor their allocation status online through various portals.The IPO was conducted between August 10 and August 12, attracting significant interest from different investor categories. Molbio Diagnostics is scheduled to be listed on BSE and NSE starting August 17.
Market Reacts to Subscription Numbers
The public offering demonstrated substantial demand across all segments. Overall, the issue received a strong subscription of 70.26 times.Institutional investors led the frenzy, with Qualified Institutional Buyers (QIBs) subscribing at an impressive 186.39 times. Non-Institutional Investors (NIIs) also responded well, achieving a subscription rate of 49.80 times. Retail investors successfully subscribed to the issue at 12.96 times.
The IPO structure included a fresh issue of 25 lakh shares worth ₹200 crore and an Offer For Sale (OFS) comprising 92 lakh shares valued at ₹739.70 crore. Molbio Diagnostics had fixed its price band between ₹768 and ₹807 per share.
Understanding The Grey Market Premium (GMP)
The grey market activity for Molbio Diagnostics continues to be robust, suggesting positive expectations ahead of listing day. The latest Grey Market Premium (GMP) is reported at around ₹154 per share.This GMP translates into a nearly 20% premium over the IPO’s upper price band of ₹807. Based on current market sentiment indicated by the GMP, Molbio Diagnostics could potentially list at approximately ₹961 per share.
Investors must note that GMP remains an unofficial indicator and is subject to rapid changes in prevailing market conditions. It reflects anticipatory sentiment but does not guarantee specific listing gains.
Strategic Capital Allocation for Infrastructure Expansion
Molbio Diagnostics plans to utilize a significant portion of the IPO proceeds towards enhancing its infrastructure and scaling its research and manufacturing capabilities. The total estimated utilisation stands at ₹205.93 crore.A major allocation, amounting to ₹125.12 crore, is earmarked for capital expenditure development. This funding will be used to establish a state-of-the-art Research and Development facility and Centre of Excellence.
Additionally, the company will commit ₹80.81 crore towards procuring necessary plant, machinery, and other equipment for its manufacturing facilities located in Goa and Visakhapatnam.
Strong Financial Performance Powers IPO Debut
Ahead of going public, Molbio Diagnostics has demonstrated healthy growth in its financial metrics. In FY26, the company's total income saw a rise of 42% year-on-year, increasing to ₹1,455 crore from ₹1,027 crore in FY25.Profitability also improved substantially, with Profit After Tax (PAT) climbing by 18%. PAT reached ₹164 crore in FY26 compared to ₹138.58 crore in the previous financial year.
This strong foundation comes as Molbio continues to expand its global healthcare footprint and strengthens its focus on rapid diagnostic solutions.
How to Verify Molbio Diagnostics Allotment Status
Investors can verify their allotment status through multiple designated platforms, provided the basis of allotment is finalised today.1. Registrar’s Website: Visit the KFinTech IPO Allotment page (ipostatus.kfintech.com/). Select Molbio Diagnostics and enter your PAN, application number, or DP/Client ID to view details.
2. NSE Website: Use the NSE IPO Allotment page (nseindia.com/invest/check-trades-bids-verify-ipo-bids). Select Equity and enter your application number and PAN for verification.
3. BSE Website: Refer to bseindia.com/investors/appli_check. Under issue type, select Equity, choose Molbio Diagnostics, and input your application number or PAN.
Quick Look: The Company Profile
Molbio Diagnostics Ltd., established in October 2000, is a global molecular diagnostics company. The company specializes in developing and commercializing rapid diagnostic solutions for infectious diseases such as COVID-19, TB, HIV, and Hepatitis B and C. It is particularly known for its proprietary Truenat platform, which delivers accurate results within an hour even in resource-constrained settings.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.